We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Resverlogix Presents at Biotech Showcase During JP Morgan Week
News

Resverlogix Presents at Biotech Showcase During JP Morgan Week

Resverlogix Presents at Biotech Showcase During JP Morgan Week
News

Resverlogix Presents at Biotech Showcase During JP Morgan Week

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Resverlogix Presents at Biotech Showcase During JP Morgan Week"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Resverlogix Corp. has announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn.

Mr. McCaffrey was excited to share developments of the Company's proposed new phase 3 clinical trial BETONMACE. "This trial represents an unprecedented opportunity to reduce major adverse coronary events "MACE" in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes."

Advertisement